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at 12 months (p = 0.030).  Conclusions: In GHD children, GH 
treatment is associated with a significant increase in fT 3 in 
the first 12 months, more pronounced in patients with more 
severe GHD, highlighting the strong correlation between se-
verity of GHD and thyroid metabolism. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Normal thyroid hormone levels are necessary for the 
optimal effect of growth hormone (GH) on the growth 
rate and a complex interdependent relationship between 
GH-insulin growth factor-1 (IGF-1) and the hypotha-
lamic-pituitary-thyroid (HPT) axis is well documented 
 [1–4] . Alterations in the HPT axis have been reported fol-
lowing GH treatment both in adults and children affected 
by GH deficiency (GHD), but the mechanism of HPT 
changes during GH replacement are not fully under-
stood. A decreased binding capacity of thyroxine-binding 
globulin (TBG)  [5–7] and a central inhibitory effect on 
thyroid-stimulating hormone (TSH) release  [8, 9] have 
been suggested. In addition, the hypothesis that GH alters 
the peripheral deiodination of thyroxine (T 4 ) to triiodo-
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 Abstract 
 Background/Aim: The significance of changes in thyroid 
function in children during growth hormone (GH) treatment 
remains uncertain. We aimed to evaluate the impact of GH 
replacement on thyroid status in children with idiopathic 
GH deficiency (GHD).  Methods: Data of 105 GHD children 
(82 M, 23 F; aged 11.13 years) during a 36-month follow-up 
were analyzed. At diagnosis the areas under the curve of GH 
(AUC GH ) were calculated during a GH-releasing hormone + 
arginine (GHRH-Arg) and insulin tolerance test.  Results: A 
significant ΔfT 3 (p < 0.001) was documented at 12 months, 
without any further change at 24 and 36 months and with-
out fT 4 and TSH modifications. Grouping patients according 
to ΔfT 3 at 12 months into those with lower (n = 80, 76%) or 
greater values than the 75th percentile (n = 25, 24%), the lat-
ter showed lower AUC GH and GH peak during a GHRH-Arg 
(p = 0.018 and 0.014, respectively) and insulin tolerance test 
(p = 0.023 and 0.020, respectively) at diagnosis. In addition, 
children with lower GH at diagnosis showed a greater ΔfT 3 
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thyronine (T 3 ) is supported by the findings from most 
studies, but with controversial data  [10–17] . Previous 
studies have been unable to demonstrate overt changes in 
the HPT  [18, 19] or the clinical relevance of these chang-
es during GH therapy  [20, 21] . Conversely, a number of 
studies have shown changes in HPT in children to be 
transient  [13, 16] or persistent up to 12 months  [15] . If 
the mentioned data demonstrate some biochemical 
changes on thyroid function tests associated with GH 
treatment, the clinical significance of these changes re-
mains uncertain and requires some scrutiny.
 The aim of this study was to further elucidate the im-
pact of GH replacement on thyroid status in a large se-
lected cohort of prepubertal children affected by isolated 
idiopathic GHD during long-term therapy and to evalu-
ate the correlation between thyroid function and bio-
chemical-auxological data.
 Materials and Methods 
 For the purpose of this study, we reviewed all files from con-
secutive children with isolated idiopathic GHD coming to the 
Units of Endocrinology of the University of Palermo from January 
1, 2005 to December 31, 2010, treated with GH for at least 12 
months. Of 145 patients newly diagnosed as affected by GHD, 105 
children (82 boys and 23 girls; mean age 11.13 ± 2.61) were studied. 
Patients with already known thyroid dysfunction, with multiple 
pituitary hormone deficiency or receiving any other kind of hor-
monal replacement treatment or drug and with a follow-up of less 
than 12 months were excluded from this analysis. All children eval-
uated were in the first stage of sexual development according to the 
criteria of Marshall and Tanner  [22] and maintained this status 
during the first 12 months of GH therapy. During the second and 
third year of follow-up, the first stages of puberty spontaneously 
began in 3 and 6 (3.7 and 8.5%, respectively) males and 1 and 2 (4.7 
and 11.1%, respectively) females ( table 1 ). The diagnosis of GHD 
was established by the clinical, auxological and biochemical crite-
ria of the GH Research Society  [23] .
 A sex hormone priming before GH stimulation tests was not 
performed in our cohort of children due to the absence of a con-
sensus about this point and controversial data from the literature 
 [24–27] . However, to reinforce the diagnosis of GHD, as auxo-
logical data we considered height (standard deviation, SD), 
height velocity (HV) 1 year before the diagnosis (SD) and height 
in comparison to the midparental height (SD). All patients un-
derwent an insulin tolerance test (ITT) and a GH-releasing hor-
mone + arginine (GHRH-Arg) test. GHD was demonstrated by 
failure of GH to respond to the two stimuli, with GH peaks <10 
and <20 μg/l, respectively. During the tests, the areas under the 
curve of GH (AUC GH ) were calculated. At therapy onset, the eu-
thyroid state for all patients was determined on the basis of nor-
mal baseline free T 3 (fT 3 ), free T 4 (fT 4 ) and TSH levels and nega-
tive anti-thyroperoxidase antibody (TPOAb) and anti-thyro-
globulin antibody (TgAb). The patients received GH once daily 
at bedtime with a pen injection system. The initial daily dose was 
Table 1.  Pubertal status (Tanner) at baseline and after 12, 24 and 36 months of GH treatment in males and fe-
males
Baseline, n (%)
(n = 105;
M/F = 82/23)
12 months, n (%)
(n = 105;
M/F = 82/23)
24 months, n (%)
(n = 100;
M/F = 79/21)
36 months, n (%)
(n = 88;
M/F = 70/18)
Pubic hair status
1
2
3
4
5
82/23 (100/100)
–
–
–
–
82/23 (100/100)
–
–
–
–
76/20 (96/95)
3/1 (3.7/4.7)
–
–
–
64/16 (91/89)
5/2 (7.1/11)
1/– (1.4/–)
–
–
Genital status (for males)
1
2
3
4
5
82 (100)
–
–
–
–
82 (100)
–
–
–
–
76 (96)
2 (2.5)
1 (1.2)
–
–
64 (91)
4 (5.7)
2 (2.8)
–
–
Breast status (for females)
1
2
3
4
5
23 (100)
–
–
–
–
23 (100)
–
–
–
–
20 (95)
1 (4.7)
–
–
–
16 (89)
1 (5.5)
1 (5.5)
–
–
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0.025 mg/kg. 5 patients (3 males and 2 females) discontinued GH 
treatment at 12 months, 12 (9 males and 3 females) discontinued 
it at 24 months, and 88 patients continued the follow-up for at 
least 36 months.
 During the study, the GH dose administered was adjusted in 
order to maintain serum IGF-1 levels within the normal range for 
sex and age. In all patients, at baseline and yearly up to 36 months 
for those who did not discontinue therapy, blood samples were 
taken and, according to our fixed internal protocol, we measured 
body height (SD), HV, body mass index (BMI), IGF-1, fT 3 , fT 4 and 
TSH. Bone age was evaluated according to the Tanner and White-
house (TW2) method  [28] . We calculated the ratio between the 
bone age and the chronological age (normal = 1) and showed the 
data as bone/chronological age ratio. The study outcome consid-
ered fT 3 , fT 4 and TSH modifications (Δ) during treatment and 
their correlations with IGF-1 and biochemical and auxological 
data. The institutional ethics committee of the University of Pa-
lermo approved this study. At the time of hospitalization, an in-
formed consent for the scientific use of the data was obtained from 
parents.
 Hormone and Biochemical Assays 
 All biochemical data were collected after overnight fasting. 
Thyroid hormone levels were measured in our centralized labora-
tory using standard methods. Serum fT 3 , fT 4 and TSH concentra-
tions were analyzed using enzyme immunoassay kits (BioCheck, 
Inc., Foster City, Calif., USA). Sensitivity values were 0.05 pg/ml 
for fT 3 and 0.05 ng/dl for fT 4 . For TSH, at concentrations of 0.1 
and 0.2 μU/ml, the interassay coefficients of variation (CVs) of 
sensitivity were determined to be 11.4 and 7.9%, respectively. The 
intra- and interassay CVs were 2.4–11.9 and 4.2–10.7% for fT 3 , 
4.5–9.8 and 3.7–11.5% for fT 4 , and 2.5–5.7 and 5.7–8.9% for TSH. 
TPOAb and TgAb were determined by immunoenzymometric as-
say (Radim SpA, Pomezia/Rome, Italy). Reference ranges of serum 
parameters for euthyroid subjects were the following: fT 3 1.4–4.2 
pg/ml, fT 4 0.8–2.0 ng/dl, TSH 0.4–4.2 μU/ml, TPOAb <100 IU/ml, 
and TgAb <100 IU/ml. During the entire study period the GH lev-
els were assayed by two immunoradiometric assays in our labora-
tory (Radim, SpA) according to availability. The sensitivity of the 
assay changed accordingly: 0.2 μg/l for the first year (2005) or 0.05 
μg/l thereafter, intraassay CVs were 2.4–4.5 and 2.5–3.9% and in-
terassay CVs were 5.8–8.5 and 3.8–5.0%, respectively. Serum total 
IGF-1 was assayed in the same laboratory using the ELISA method 
(OCTEIA IGF-1 Kit; IDS Inc., Fountain Hills, Ariz., USA). The 
sensitivity of the method was 1.9 μg/l; inter- and intraassay CV 
values were 7–7.1 and 2.3–3.5% and IGF-1 levels were 90.7–186 
and 66.7–120.9 μg/l, respectively. The normal ranges (males and 
females combined) of total IGF-1 levels (μg/l) were 12–108 (0–1 
years), 13–100 (1–3 years), 26–280 (3–6 years), 85–230 (6–9 years), 
98–404 (9–12 years), 142–525 (12–15 years), and 146–415 (15–20 
years).
 Statistical Analysis 
 SPSS version 17 was used for data analysis. Baseline character-
istics were presented as mean ± SD for continuous variables, and 
rates and proportions were calculated for categorical data. Nor-
mality of distribution for quantitative variables was assessed with 
the Kolmogorov-Smirnov test. Differences between groups in uni-
variate analysis were detected with the Mann-Whitney test. p < 
0.05 was considered statistically significant.
 Results 
 The baseline clinical and biochemical features of pa-
tients are shown in  table 2 . As expected, a significant in-
crease in weight, height, BMI and bone age was docu-
mented annually during the entire follow-up ( table 3 ). In 
all children, HV was 8.4, 6.9 and 6.5 cm at 12, 24 and 36 
months of therapy, respectively (data not shown). IGF-1 
levels showed a significant increase after 12 months 
(314.68 ± 193.25 vs. 98.83 ± 47.94; p < 0.001) and 36 
months (349.90 ± 145.88 vs. 330.30 ± 172.95; p = 0.012) 
of GH treatment, while no significant difference was 
shown after 24 months (330.30 ± 172.95 vs. 314.68 ± 
193.25; p = 0.192), although IGF-1 remained significant-
ly higher than the pre-therapy levels (p < 0.001). A sig-
nificant increase in fT 3 (ΔfT 3 ) (4.13 ± 0.53 vs. 3.10 ± 0.94 
pg/ml; p < 0.001) was documented after 12 months of GH 
treatment, without any further change after 24 and 36 
months, although it remained significantly higher than 
the pre-therapy values. ΔfT 3 did not show any correlation 
with the auxological and biochemical parameters during 
the entire follow-up, or with ΔfT 4 and ΔTSH. Similarly, 
no correlation between ΔfT 3 and ΔIGF-1 was shown 
Table 2.  Baseline clinical and biochemical features of all patients at 
diagnosis
Parameter Subjects (%)
Males
Females
82 (78)
23 (22)
Age, years 11.13 ± 2.61
BMI 17.57 ± 3.05
Height (SD)  – 2.11 ± 0.89
Height in comparison to the midparental 
height (SD)  – 1.93 ± 0.12
Height velocity 1 year before the diagnosis (SD)  – 1.58 ± 0.23
Bone age, years   9.04 ± 2.67
Bone/chronological age ratio   0.79 ± 0.09
IGF-1, μg/l 98.83 ± 47.94
Basal GH, μg/l 0.47 ± 0.64
AUCGH during ITT 203.86 ± 181.89
Peak GH during ITT, μg/l 2.71 ± 2.18
AUCGH during GHRH+Arg test 745.68 ± 505.16
Peak GH during GHRH+Arg test, μg/l 9.32 ± 6.08
fT3, pg/ml 3.05 ± 0.91
fT4, ng/dl 1.25 ± 0.24
TSH, μU/ml 1.98 ± 0.84
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(data not shown). No significant variation in fT 4 and TSH 
levels was observed during follow-up ( table 3 ).
 Arbitrarily grouping all patients according to the ΔfT 3 
at 12 months into those with Δ lower (80 patients, 76%) 
or greater (25 patients, 24%) than the 75th percentile, the 
latter showed significantly lower AUC GH during GHRH-
Arg (465 ± 273 vs. 785 ± 503; p = 0.018) and ITT (130 ± 
132 vs. 255 ± 200; p = 0.023). In addition, a lower GH peak 
during GHRH-Arg (p = 0.014) and ITT (p = 0.020) has 
been documented. These children also showed lower fT 3 
levels at baseline (1.81 ± 0.72 vs. 3.53 ± 0.54 pg/ml; p < 
0.001), without any difference in fT 4 and TSH levels. No 
significant differences in auxological parameters were de-
tected between the two groups of patients ( table 4 ).
 To support these data, we evaluated fT 3 and its Δ 
grouping in all children according to the GH levels at di-
agnosis into those with GH peak after ITT lower (26 pa-
tients, 25%) or greater (79 patients, 75%) than the 25th 
percentile (identified in 1.30 μg/l) to highlight children 
with more severe GHD. These latter showed lower, al-
though not statistically significant, baseline fT 3 levels 
(3.42 ± 1.79 vs. 3.57 ± 1.03 pg/ml; p = 0.099) and a sig-
nificant greater ΔfT 3 (1.09 ± 1.74 vs. 0.96 ± 0.88; p = 
0.030) than children with higher GH levels ( table 5 ).
 Discussion 
 This retrospective analysis of a large cohort of prepu-
bertal children affected by idiopathic GHD demonstrated 
that children with more severe hormone deficiency show 
lower fT 3 levels at diagnosis and a significant increase in 
Table 3.  Variation of clinical and biochemical parameters after 12, 24 and 36 months of GH treatment
Parameter Baseline
(n = 105)
12 months
(n = 105)
24 months
(n = 100)
36 months
(n = 88)
p* p** p***
Weight, kg 30.76 ± 10.88 34.77 ± 12.05 37.34 ± 13.17 39.57 ± 12.63 <0.001 <0.001 <0.001
Height (SD) –2.11 ± 0.89 –1.73 ± 0.75 –1.44 ± 0.76 –1.03 ± 0.85 <0.001 <0.001 <0.001
BMI 17.57 ± 3.05 17.75 ± 2.97 18.15 ± 3.33 17.98 ± 3.29 0.005 <0.001 0.049
Bone age, years 9.04 ± 2.67 10.70 ± 2.56 11.71 ± 2.25 12.69 ± 2.04 <0.001 <0.001 <0.001
Bone/chronological age ratio 0.79 ± 0.09 0.88 ± 0.06 0.94 ± 0.05 0.96 ± 0.04 <0.001 <0.001 <0.001
IGF-1, μg/l 98.83 ± 47.94 314.6 ± 193.2 330.3 ± 172.9 349.9 ± 145.8 <0.001 0.192 0.012
fT3, pg/ml 3.10 ± 0.94 4.13 ± 0.53 4.12 ± 0.53 4.21 ± 0.53 <0.001 0.788 0.681
fT4, ng/dl 1.25 ± 0.24 1.25 ± 0.28 1.19 ± 0.25 1.19 ± 0.23 0.982 0.236 0.981
TSH, μU/ml 1.98 ± 0.84 1.92 ± 0.97 1.95 ± 1.03 1.51 ± 0.54 0.254 0.847 0.250
 Difference between * 12 months and baseline, ** 24 and 12 months, and *** 36 and 24 months.
Table 4.  Differences of auxological and biochemical parameters between patients with an increase in fT3 (ΔfT3) 
at 12 months of GH treatment according to the ≤75th and >75th percentile
ΔfT3 at 12 months
≤75th percentile
(n = 80; 76%)
ΔfT3 at 12 months
>75th percentile
(n = 25; 24%)
p
AUCGH-ITT 255.72 ± 200.03 130.99 ± 132.38 0.023
AUCGH-GHRH-Arg 785.99 ± 503.15 465.63 ± 273.63 0.018
Peak GH during ITT, μg/l 3.30 ± 2.31 1.70 ± 1.76 0.020
Peak GH during GHRH+Arg test, μg/l 9.74 ± 5.97 5.97 ± 3.60 0.014
Baseline IGF-1, μg/l 98.53 ± 48.13 99.40 ± 60.49 0.953
Baseline fT3, pg/ml 3.53 ± 0.54 1.81 ± 0.72 <0.001
HV at 12 months, cm 8.54 ± 2.33 8.13 ± 2.17 0.550
ΔIGF-1 at 12 months 222.48 ± 175.47 224.32 ± 231.30 0.973
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fT 3 during the first 12 months of treatment, without sig-
nificant changes in fT 4 and TSH levels and with no sig-
nificant correlation with auxological data.
 First of all, it is important to specify that the recruit-
ment and inclusion criteria of children in this study was 
based on the diagnosis of overt GHD made by the unani-
mously recognized GH stimulation tests  [23] , without a 
sex hormone priming test. There is no consensus in the 
literature about the significance of the diagnosis of GHD 
in children in the absence of priming test. If some author 
considers that omission of priming during the preadoles-
cent period decreases the specificity of GH stimulation 
tests and increases the percentage of false-positive diag-
nosis results  [24] , others believe that it leads only to a 
temporary augmentation of GH secretion and may lead 
to underdiagnosis of peripubertal children that could 
have benefited from GH treatment  [26] .
 Recently, Lazar and Phillip  [25] have reviewed the 
available published data and suggested that priming 
should be considered only in adolescents with pubertal 
delay, girls aged 11.5–12 years and boys aged 13–13.5 
years, exhibiting no evidence of puberty or only initial 
signs. The children evaluated in our study showed a 
mean chronological age of 11.34 ± 2.99 years (boys) and 
9.87 ± 2.14 years (girls). In line with these data, we 
thought that a priming test would probably not have 
been useful.
 This aspect could represent a hypothetical bias of this 
study and could decrease the specificity of the results ob-
tained, even if the sensitivity of the thyroid data demon-
strated cannot be affected by this aspect.
 The relationship between GH and thyroid function 
has been evaluated by numerous studies, but the clinical 
data about the effect of GH replacement on thyroid hor-
monal levels in patients with GHD are contradictory and 
no clear correlation has been observed between thyroid 
hormones and auxological and biochemical data.
 In normal healthy adults, short-time GH administra-
tion resulted in a reduction in total T 4 and fT 4 , an increase 
in total T 3 and a concomitant marked decrease in TSH 
 [11] . Following GH administration, some studies have 
demonstrated different degrees of thyroid hormone level 
changes, such as a reduction in serum fT 4  [8, 29] or an 
increase in fT 3  [10, 11, 16, 30] , while other studies have 
not confirmed these observations  [18, 20, 21, 30–32] . It 
has been suggested that the incidence of both central and 
peripheral hypothyroidism should be taken into account 
during recombinant human GH administration, as hypo-
thyroidism may worsen the response to therapy. Some 
authors have demonstrated that GH therapy can unmask 
central hypothyroidism, leading to an attenuation of the 
benefit of GH in adult GHD patients with organic pitu-
itary disease or multiple pituitary hormone deficiencies 
 [15, 17] . For these reasons, Behan et al.  [33] recently rec-
ommended that patients starting GH should have their 
thyroid function monitored closely, particularly in the 
first 6 months, to identify those who will develop hypo-
thyroidism.
 Some researchers described the possibility of a de-
crease in TSH secretion, however within the normal 
range, in children after 6 and 12 months of GH therapy. 
This phenomenon is probably connected with a direct ef-
fect of administered GH on the release of somatostatin, a 
natural TSH inhibitor  [34] . On the other hand, Smyczyn-
ska et al.  [35] showed a significant decrease in fT 4 serum 
concentrations during the initial 3–6 months of GH ad-
ministration, with a concomitant significant increase in 
IGF-1 levels in 75 children with various disorders of GH 
secretion, with a lower improvement of HV in those who 
revealed overt hypothyroidism. For these reasons, an ear-
lier assessment of THS and fT 4 concentration after GH 
therapy onset or levothyroxine administration from the 
beginning of GH therapy has been proposed. Conversely, 
our data demonstrated that GH replacement therapy 
does not induce hypothyroidism in children with idio-
pathic GHD. In our study, no significant change in TSH 
levels was observed during a 36-month follow-up. These 
findings, in line with the data of Wyatt et al.  [13] , seem to 
be discordant with other studies, probably for many rea-
sons. Important factors which may explain the lack of 
consistent results are the different hormone assay meth-
ods, the small sample size of many studies and the differ-
ent criteria for selection of the populations studied. In 
addition, the majority of published data are limited to the 
first 6–12 months of follow-up. To avoid these biases, for 
this analysis we selected the study population excluding 
patients with multiple pituitary hormone deficiency or 
Table 5.  Baseline fT3 and its increase (ΔfT3) after 12 months of GH 
treatment in patients with GH peak after ITT according to the 
≤25th and >25th percentile
GH peak 
after ITT
<25th percentile
(n = 26; 25%)
GH peak 
after ITT
≥25th percentile
(n = 79; 75%)
p
Baseline fT3, pg/ml 3.42 ± 1.79 3.57 ± 1.03 0.099
ΔfT3 at 12 months 1.09 ± 1.74 0.96 ± 0.88 0.030
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receiving any kind of hormonal replacement treatment. 
In addition, we also excluded all patients with a follow-up 
of less than 12 months in order to have a homogeneous 
study population with a longer follow-up.
 A few years ago, Jorgensen et al.  [9] showed that GH 
administration stimulated peripheral T 4 to T 3 conversion 
in a dose-dependent manner in GHD adults, and Rezvani 
et al.  [21] observed the same data in GHD children. These 
findings are partially concordant with our study. Indeed, 
our data demonstrated that the change in TSH and fT 4 
secretion during GH substitution is less significant than 
fluctuations in fT 3 concentrations. In our patients, a sig-
nificant increase in fT 3 at 12 months of therapy is docu-
mented in the majority of cases, in line with the data of 
Seminara et al.  [16] , without a significant relationship 
with IGF-1 and without any impact on catch-up growth. 
These changes, independently of TSH levels, might be an 
expression of the metabolic status of patients at that mo-
ment and could be explained by an increased GH-in-
duced T 4 to T 3 deiodination, as previously reported  [12, 
14, 36] . The evidence that GHD reduces T 4 to T 3 conver-
sion and GH improves T 4 to T 3 conversion through iodo-
thyronine deiodinase activity is well known in animal 
models  [37–39] . In our patients, fT 3 increase does not oc-
cur during long-term follow-up (24 and 36 months), 
when fT 3 does not change any further. To support this 
hypothesis, we grouped the children according to the de-
gree of fT 3 increase at 12 months of therapy and analyzed 
the difference in auxological and biochemical parameters 
between the children with a more pronounced increase 
and those with a slight increase in fT 3 . Subsequently, we 
evaluated fT 3 and its Δ grouping in all children according 
to the GH levels at diagnosis to highlight children with 
more severe GHD. Our data demonstrated that the in-
crease in fT 3 levels after 12 months of treatment appears 
to be more pronounced in children with a more severe 
GHD at diagnosis, documented by GH levels during the 
stimulation tests performed at diagnosis. We speculate 
that a possible explanation of these data could be that 
children with lower GH levels at diagnosis, in terms of 
both peak and AUC during the test, also have a decreased 
T 4 to T 3 conversion due to more severe GHD. Therefore, 
at therapy onset these subjects seem to restore normal fT 3 
levels, with an obvious greater increase than children with 
less severe GHD. It is probably for this reason that the 
higher ΔfT 3 does not correlate with the auxological data 
in terms of height, weight, bone age and HV.
 A limit of this study could be represented by the lack of 
information about the total T 3 and T 4 , reverse T 3 and TBG 
levels, probably useful to better understand these interest-
ing mechanisms. In fact, the role of a decreased binding 
capacity of TBG or a reduction in reverse T 3 cannot be 
ruled out as additional mechanisms. However, this is a 
retrospective study and our internal protocol of manage-
ment of GHD children does not include these evaluations.
 In conclusion, in this study we demonstrated that 
GHD in children seems to reduce T 4 to T 3 conversion and 
the onset of GH treatment is associated with a significant 
increase in fT 3 levels in the first 12 months of therapy. The 
more pronounced increase in fT 3 after 12 months of treat-
ment happens in children affected by more severe GHD, 
although without significant correlation of these changes 
with the auxological parameters. These data, partially 
confirming previous studies, for the first time highlight 
the strong correlation between the severity of GHD and 
the thyroid metabolism. Further studies carried out on a 
broad unselected group of children on GH therapy (i.e. 
organic GHD, Turner syndrome, small for gestational 
age) and a stratification of them according to the severity 
of GHD or the GH dose, could give more information 
about the real impact of GH therapy on thyroid function 
and could be useful to understand the utility of the rou-
tine monitoring of thyroid function in children during 
GH treatment.
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